Acute kidney injury (AKI) is a common and life-threatening condition associated with cell death, where ferroptosis plays a critical role. Chemerin, primarily produced in white adipose tissue, has ...

Rhabdomyolysis is a clinical syndrome characterised by the breakdown of skeletal muscle fibres and the subsequent release of intracellular constituents into the bloodstream. Central to the cascade is ...

Kidney diseases are becoming increasingly common, yet many people struggle to understand the difference between sudden kidney damage and long-term kidney disease. Two major conditions often discussed ...

A new study published in the journal eGastroenterology provides an updated assessment of the diagnosis, pathophysiology, and treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI). This ...

HRS-AKI diagnostic criteria. HRS-AKI is characterised by a decrease in renal blood flow and glomerular filtration rate. It is diagnosed in the context of a patient with cirrhosis with ascites who ...

Acute Kidney Injury, or AKI, is a common yet often overlooked condition that can develop suddenly and affect how your kidneys function. It is frequently linked to multiple underlying causes, making it ...

Boys and men carry a greater risk for acute kidney injury (AKI) than women and girls across all age groups, according to a recent study published in the American Journal of Kidney Diseases. "Acute ...

The differential diagnosis is vast but can be more easily managed by breaking down the possibilities into three main categories of AKI causes: prerenal, intrinsic, and postrenal.

Pathophysiology of hepatorenal syndrome-acute kidney injury. Cirrhosis leads to an elevation in intrahepatic vascular resistance. Splanchnic vasodilation increases the production of vasodilators ...

Postoperative AKI is more likely among surgery patients who experience intraoperative hypotension as well as those receiving the vasopressor norepinephrine. Both intraoperative hypotension and ...

TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today ...